Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07380646CT.gov the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer | — | Recruiting | — | — | — |
NCT07362914CT.gov Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions | — | Recruiting | — | — | — |
NCT06382948CT.gov Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | — | Recruiting | — | — | — |
NCT06300099CT.gov Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block | — | Unknown | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04603911CT.gov RCT Comparing ESPB Solutions in Breast Surgery | — | Completed | — | — | — |
NCT04019834CT.gov Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy | — | Completed | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03348696CT.gov Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients | — | Completed | — | — | — |
Show 12 more trialsShow fewer
NCT03386617CT.gov AKY15-HK-301_NEPA Study | — | Active Not Recruiting | — | — | — |
NCT03079219CT.gov Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients | — | Completed | — | — | — |
NCT02525718CT.gov Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction | — | Completed | — | — | — |
NCT02069093CT.gov Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01698281CT.gov Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT01332630CT.gov TPI 287 in Breast Cancer Metastatic to the Brain | — | Completed | — | — | — |
NCT00832338CT.gov Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores | — | Terminated | — | — | — |
NCT00721409CT.gov Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00404066CT.gov Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | — | Completed | — | — | — |
NCT00253318CT.gov RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00293384CT.gov Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Beijing Biostar Pharmaceuticals Co., Ltd. | Approved | BB · 65 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →